Drug Price Trends for FT MUCUS DM ER

Average Pharmacy Cost for FT MUCUS DM ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT MUCUS DM ER 600-30 MG TAB	70677-1050-01	0.41660	EACH	2025-03-19
FT MUCUS DM ER 600-30 MG TAB	70677-1050-01	0.42053	EACH	2025-02-19
FT MUCUS DM ER 600-30 MG TAB	70677-1050-01	0.43475	EACH	2025-01-22
FT MUCUS DM ER 600-30 MG TAB	70677-1050-01	0.43979	EACH	2024-12-18
FT MUCUS DM ER 600-30 MG TAB	70677-1050-01	0.45602	EACH	2024-11-20
FT MUCUS DM ER 600-30 MG TAB	70677-1050-01	0.41977	EACH	2024-10-23

Market Analysis and Price Projections for Expectorant Drugs: Focus on FT MUCUS DM ER

Introduction to Expectorant Drugs

Expectorant drugs, such as those containing guaifenesin and dextromethorphan, are crucial in the management of respiratory conditions by helping to thin and loosen mucus, making it easier to cough up. This class of drugs is widely used for treating common colds, influenza, pneumonia, and other respiratory ailments.

Market Size and Growth Projections

The global expectorant drugs market is anticipated to experience significant growth over the coming years. Here are some key projections:

• The expectorant drugs market is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.5% from 2024 to 2029, reaching a market size of USD 120 million by 2029 from USD 100 million in 2024[1].
• On a broader scale, the global expectorant drugs market is forecasted to expand from USD 16.8 billion in 2023 to USD 22.9 billion by 2030, also at a CAGR of 4.5%[3].

Regional Market Analysis

North America

North America is expected to dominate the expectorant drugs market due to several factors:

• High prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD), emphysema, and chronic bronchitis.
• Presence of key market players and significant research and development (R&D) expenditures.
• A rapidly growing older population, which is more susceptible to respiratory conditions[1].

Asia Pacific

The Asia Pacific region is identified as the fastest-growing market for expectorant drugs. This growth is driven by increasing healthcare infrastructure, rising awareness of respiratory health, and a large patient population suffering from respiratory diseases[1].

Key Players and Market Concentration

The expectorant drugs market has a medium level of concentration, with several key players dominating the market. Companies like Reckitt Benckiser (Mucinex), Aurobindo Pharma, and Dr. Reddy's Laboratories are significant players in this sector. These companies are continuously innovating and expanding their product portfolios to capture a larger market share[1][4].

Pricing and Cost Analysis

FT MUCUS DM ER Pricing

FT MUCUS DM ER, which typically contains guaifenesin and dextromethorphan, is priced competitively in the market.

• For a supply of 20 tablets of Mucus Relief DM (a similar formulation), the cost is around $13, depending on the pharmacy[2].
• Prices can vary based on the quantity and formulation, but generally, extended-release tablets are priced in the range of $0.65 to $1.47 per unit[2].

Generic and Brand Variations

Generic versions of these medications are available, which can significantly reduce the cost for consumers. For example, generic versions of Mucus Relief DM and Mucus Relief D can be found at prices starting from $11.08 for 18 tablets[5].

Patient Assistance and Copay Programs

Patient assistance programs (PAPs) and copay cards are often available to help reduce the financial burden on patients. However, for FT MUCUS DM ER and similar medications, no specific PAPs were found. Patients are advised to consult their healthcare providers for information on available programs in their area[2][5].

Market Drivers

Increasing Prevalence of Respiratory Diseases

The rising incidence of respiratory diseases such as COPD, asthma, and pneumonia drives the demand for expectorant drugs. For instance, according to the CDC, 4.6% of adults in the U.S. reported being diagnosed with COPD, emphysema, or chronic bronchitis in 2022[1].

Advancements in Pharmaceutical Technology

Continuous innovation in respiratory care pharmaceuticals, including faster FDA approvals and the development of extended-release formulations, contributes to market growth. Recent approvals, such as Granules India's guaifenesin extended-release tablets, enhance the product portfolio and patient compliance[4].

Growing Demand in Hospital and Clinical Settings

The increasing demand for guaifenesin in hospitals and clinics for treating various respiratory conditions is a significant market driver. The growth in the pharmaceutical sector and advancements in medical infrastructure further boost the demand for these drugs[4].

Market Challenges

Availability of Substitutes and Potential Side Effects

One of the major challenges facing the guaifenesin market is the availability of substitute medications and potential side effects associated with guaifenesin. These factors can impact market growth and patient preference[4].

Recent Developments

• Granules India: Received approval for guaifenesin extended-release tablets in February 2020, expanding the OTC product portfolio in the US[4].
• Aurobindo Pharma: Received approval from the USFDA for guaifenesin expectorant tablets in October 2019[4].
• Dr. Reddy's Laboratories: Launched an OTC store-brand equivalent of Mucinex D extended-release tablets in July 2019, enhancing the product portfolio[4].

Key Takeaways

• The global expectorant drugs market is projected to grow at a CAGR of 4.5% from 2024 to 2029.
• North America dominates the market due to high prevalence of respiratory diseases and significant R&D expenditures.
• The Asia Pacific region is the fastest-growing market driven by increasing healthcare infrastructure and awareness.
• Pricing for FT MUCUS DM ER and similar formulations is competitive, with generic versions available to reduce costs.
• Patient assistance programs, though limited, can help reduce the financial burden on patients.
• Market growth is driven by increasing respiratory disease prevalence, pharmaceutical innovations, and growing demand in hospital settings.

FAQs

What is the expected market size of the expectorant drugs market by 2029?

The expectorant drugs market is expected to reach USD 120 million by 2029[1].

Which region is the fastest-growing market for expectorant drugs?

The Asia Pacific region is identified as the fastest-growing market for expectorant drugs[1].

What are the key drivers of the expectorant drugs market?

Key drivers include the increasing prevalence of respiratory diseases, advancements in pharmaceutical technology, and growing demand in hospital and clinical settings[1][4].

Are there any patient assistance programs available for FT MUCUS DM ER?

No specific patient assistance programs were found for FT MUCUS DM ER, but patients can consult their healthcare providers for available programs in their area[2][5].

What are the common side effects associated with guaifenesin?

While guaifenesin is generally well-tolerated, potential side effects include dizziness, headache, and stomach upset. It is essential to follow the prescribed dosage and consult a healthcare provider if any side effects occur[2].

How does the pricing of FT MUCUS DM ER compare to other similar medications?

The pricing of FT MUCUS DM ER is competitive, with costs ranging from $0.65 to $1.47 per unit, depending on the quantity and formulation. Generic versions can further reduce the cost[2][5].

Sources

1. Mordor Intelligence: Expectorant Drugs Market Size & Share Analysis.
2. Drugs.com: Mucus Relief DM Prices, Coupons, Copay Cards & Patient Assistance.
3. Persistence Market Research: Expectorant Drugs Market Size & Top Players Analysis, 2030.
4. IndustryARC: Guaifenesin Market Size Report, 2022-2027.
5. Drugs.com: Mucus Relief D Prices, Coupons, Copay Cards & Patient Assistance.